Organon & Co. Investigation - OGN
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.
If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more, you can provide your information in the form on this page. You can also contact attorney J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.
THE COMPANY: Organon is a global healthcare company with a primary focus on improving the health of women.
THE REVELATION: On May 1, 2025, Organon revealed that it was cuttings its dividend by approximately 90%. Following this news, the price of Organon stock fell more than 28%.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.